Argenx Se (ARGX) Current Deferred Revenue (2015 - 2020)
Argenx Se's (ARGX) quarterly Current Deferred Revenue came in at $306.4 million in Q4 2020, down 4.66% YoY from $321.4 million in Q1 2020, and up 313.4% on a QoQ basis from $74.1 million in Q2 2020.
Argenx Se (ARGX) Current Deferred Revenue (2015 - 2020) Analysis & Trends
Argenx Se (ARGX) has 6 years of Current Deferred Revenue data on file, last reported at $306.4 million in Q4 2020.
- Quarterly Current Deferred Revenue fell 4.66% year-over-year to $306.4 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $306.4 million (down 4.66% YoY) and the FY2020 annual result came in at $46.3 million, down 42.99% from the prior year.
- Current Deferred Revenue climbed to $306.4 million in Q4 2020, from $74.1 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $321.4 million in Q4 2019 to a low of $2.5 million in Q4 2018.
- A 5-year average of $91.4 million and a median of $23.7 million in 2017 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2018 — Current Deferred Revenue plunged 83.53% — and 2019, when it surged 12930.63%.
- Tracing ARGX's Current Deferred Revenue over 5 years: stood at $21.7 million in 2016, then slumped by 31.11% to $15.0 million in 2017, then slumped by 83.53% to $2.5 million in 2018, then surged by 12930.63% to $321.4 million in 2019, then retreated by 4.66% to $306.4 million in 2020.
- The last three Current Deferred Revenue figures came in at $306.4 million (Q4 2020), $74.1 million (Q2 2020), and $321.4 million (Q4 2019), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 306.42 Mn |
| Jun 30, 2020 | 74.12 Mn |
| Dec 31, 2019 | 321.41 Mn |
| Jun 30, 2019 | 51.53 Mn |
| Dec 31, 2018 | 2.47 Mn |
| Jun 30, 2018 | 5.86 Mn |
| Dec 31, 2017 | 14.98 Mn |
| Jun 30, 2017 | 23.72 Mn |
| Dec 31, 2016 | 21.74 Mn |
| Dec 31, 2015 | 4.54 Mn |